You are here
Generic Dasatinib in india
2013.... Novartis case Indian Supreme Court
The Indian supreme court has refused to allow one of the world's leading pharmaceutical companies to patent a new version of a cancer drug, a decision campaigners hailed as a major step forward in enabling poor people to access medicines in the developing world.
Novartis lost a six-year legal battle after the court ruled that small changes and improvements to the drug Glivec did not amount to innovation deserving of a patent. The ruling opens the way for generic companies in India to manufacture and sell cheap copies of the drug in the developing world and has implications for HIV and other modern drugs too.
Campaigners were jubilant. A ruling in Novartis's favour would have reduced poor people's access to the drug, said Jennifer Cohn, of Médecins Sans Frontières (MSF). "The fact that India says patents are to reward innovation as opposed to small changes does stay true to the concept of what a patent should be."
But Novartis said the decision "discourages future innovation in India". Ranjit Shahani, the firm's vice-chairman and managing director in India, said the ruling was "a setback for patients that will hinder medical progress for diseases without effective treatment options".
He said the Swiss company will be cautious about investing in India, especially over introducing new drugs, and seek patent protection before launching any new products. It will continue to refrain from research and development activities in the country. "The intellectual property ecosystem in India is not very encouraging," Shahani told reporters in Mumbai after the ruling
Company: Bristol-Myers Squibb
Indication(s): Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
Sales: $2 billion (2018)
Generic(s) approved? No
Patent expiration dates in 2020: April 13 (treatment of CML); June 28 (treatment of protein tyrosine kinase-associated disorder and cancer); Oct. 13 (pediatric use); Dec. 28 (pediatric use)
I only know about 'Dasashila' made by shilpa pharma,its mrp is around Rs 7000-8000 but we can buy it from wholesalr-retail medical stores by around Rs 4000-5000 ,100 mg.
I was on nilotinib for 10 months & there after i'm on imatinib. Even aftet 30 months my pcr is 0.188%(is).
So i want to opt for dasanib.
Very soon many indian pharma company generic dasanib will be available.
Hi sir....this is keerthi , i am a 18 year old cml patient from hyderabad...
Since 2011 i've been a cml patient...
I started my medication with imatinib 300mg, i've would recieve imatinib for free of cost as i was linked with novartis...but in 2019 feb , my doc just advised us to stop imatinib as they weren't giving any responce..so i was asked to take dasatinib(sprycel)140mg ...
They cost me around 17,000.every 1 month..
Its really hard to meet the medical expences for a middle class family like mine... I just saw ur thread right now and i am shocked to see that dasatinib is available in that lower prices...so could u please share me complete info about where u get these medicines for lower prices around hyderabad, india...Thank u sir
Dasatinib patent just expired in april 2020 in india. As of now, dr.reddys lab and shilpha medicare are making dasatinib bioequvalents.
Dr.reddys cost for dasatinib is around rupees 5400 for a strip of 30 tablets(100mg).
Shilpa Medicare cost for dasatinib is 5400 for a bottle 30 tablets (100mg). bottle of 60 tablets (50mg) is rupees 5150.
Shilpa Medicare is providing patient assistance program .if you buy 2 bottles,they provide you a bottle free of cost i.e 2+1 scheme.which means you spend around rupees 3500 for dasatinib (100mg) per month.
Dr.reddy lab don't provide this scheme.but if you stress that Shilpa Medicare is giving 2+1 scheme to dr reddys representatives,they might consider giving the same scheme as shilpa Medicare is providing.just stress it.
I just switched to dasatinib from nilotinib.i buy dasatinib from shilpa medicare.shilpa Medicare is less known brand than dr.reddys but no need to worry,all generics are bioequvalents to original dasatinib.
Dasatinib 140 mg costs around 7800 rupees per month.whatever mg you take, shilpa Medicare provides 2+1 scheme for life long(they told me this scheme is life long)
Shilpa Medicare sudhir chopra general manager phone no.8879774529,. 9810703194.
For dr.reddys lab just contact their customer care number (website) they provide you representative number. Best wishes keerthy.